Thanks @Eqz. I’m currently reading through the broker report...

Thanks @Eqz.

I’m currently reading through the broker report which is really detailed as you said. It’s all pretty much as expected with PromarkerD, but other things in our pipeline, I would like to spend a little bit more time on reading.

I’m very pleased that it is very reflective of our own research we have done here in regards to Janssen/Invokana collaboration; Renalytix AI test (their amazing MC in comparison to PIQ & reflective value); PromarkerD MS can be used currently in the USA in CLIA approved labs (~260,000 labs currently) it does not require FDA approval (the IVD does), we are just waiting on the CTP code for billing (applied for) & at US$50 per test & the cost savings in ESKD, a very attractive option for this test to be covered under Medicare in it’s own right in comparison to $1000 per test with RenalytixAI, of whether this becomes a CDx for SLGT2 inhibitors (Invokana) & fast tracking of commercialisation by Janssen.

There are so many positives here & this is a company sponsored broker report, not an ASX ANN. If our expected time frame for Janssen results in a clinical trial of ~3600 patients is a bit out (nothing unusual in biotech investing), I’m happy to wait too. As @wisdomofsilence posted expected in “the coming months” is quite loosely termed, so we shall see for those who choose to hang around in such a “dog’s breakfast” of a market at the moment as you said @Eqz.

There is sooo much negativity & doom & gloom out there at the moment with the current situation with COVID19. I’m over it, both on the coal face of public health & with markets as an investor. We are all going to take hits with this virus, it will depend on how we deal with it personally, both healthwise (including psychologically) & financially. It’s everyone’s individual choice whether they allow themselves to end up a paranoid basket case or just get on with life.

One thing for sure is, this is a temporary health crisis & it won’t make a permanent health crisis go away (DKD/CKD/ESKD) & the global health costs involved.

If anything, you would envisage that Govts would be looking to mitigate costs in other clinical areas, prevent ‘bums in beds’ in hospitals with primary & preventative health care in order to deal with the COVID19 outbreak, both financially & clinically with resources.

Diabetes, cardiac disease & chronic kidney disease are all risk factors for patients becoming seriously unwell with COVID19. They aren’t all “just old people” either that are at risk, which I think is some kind of false sense of security for personal wellbeing on social media, just like the people who feel the need to buy copious amounts of toilet paper.

Stay well all & thanks for a bit of sunshine through the clouds as usual @Eqz. GLTAH